C. Difficile infection: Changing epidemiology and management paradigms

Clinical and Translational Gastroenterology

Volumn 6, Issue 7, 2015, Pages

  Vindigni, Stephen M ^a   Surawicz, Christina M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; FIDAXOMICIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; VANCOMYCIN;

AGE; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CANADA; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DISINFECTION; ENZYME IMMUNOASSAY; ERADICATION THERAPY; EUROPE; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL SURGERY; GASTROSTOMY; HAND WASHING; HEALTH CARE COST; HEALTH CARE FACILITY; HUMAN; INCIDENCE; INFECTION PREVENTION; JEJUNOSTOMY; LACTOBACILLUS RHAMNOSUS; LENGTH OF STAY; MORTALITY; PATIENT CARE; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROCESSED MEAT; PROTECTIVE EQUIPMENT; REVIEW; RISK FACTOR; SACCHAROMYCES BOULARDII; UNITED STATES;

EID: 84989298221     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2015.24     Document Type: Review

References (56)

1. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-498.
2. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010; 4: 409-416.
3. Khanna S, Pardi DS, Aronson SL et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012; 107: 89-95.
4. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12: 409-415.
5. To KB, Napolitano LM. Clostridium difficile infection: update on diagnosis, epidemiology, and treatment strategies. Surg Infect (Larchmt) 2014; 15: 490-502.
6. Surawicz CM Clostridium difficile infection: risk factors, diagnosis and management. Curr Treat Options Gastroenterol 2015; 13: 121-129.
7. Bartlett JG, Chang TW, Gurwith M et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298: 531-534.
8. Bartlett JG Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S4-S11.
9. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55(SUPPL. 2): S65-S70.
10. O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136: 1913-1924.
11. Lucado J, Gould C, Elixhauser A. Clostridium difficile Infections (CDI) in Hospital Stays, 2009: Agency for Healthcare Research and Quality; 2012, cited 19 January 2015. Available from http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf.
12. Steiner C, Barrett M, Sun Y, Weiss A. HCUP Projections: Clostridium difficile Hospitalizations 2003-2014: US Agency for Healthcare Research and Quality; 2014. HCUP Projections Report #2014-03. Available from http://www.hcup-us.ahrq.gov/reports/projections/2014-03.pdf.
13. Minino A, Xu J, Kochanek K. Deaths: Preliminary Data for 2008 Hyattsville. National Center for Health Statistics: MD, USA, 2010; 59 Available from http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59-02.pdf.
14. Pépin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-472.
15. Asensio A, Vaque-Rafart J, Calbo-Torrecillas F et al. Increasing rates in Clostridium difficile infection (CDI) among hospitalised patients, Spain 1999-2007. Euro Surveill 2008; 13: pii:18943.
16. Burckhardt F, Friedrich A, Beier D et al. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis 2008; 14: 691-692.
17. Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc 2012; 87: 1106-1117.
18. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-2056.
19. Ricciardi R, Ogilvie JW, Roberts PL et al. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum 2009; 52: 40-45.
20. Boyce JM, Ligi C, Kohan C et al. Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs. Infect Control Hosp Epidemiol 2006; 27: 479-483.
21. Gordin FM, Schultz ME, Huber RA et al. Reduction in nosocomial transmission of drugresistant bacteria after introduction of an alcohol-based handrub. Infect Control Hosp Epidemiol 2005; 26: 650-653.
22. Taori SK, Wroe A, Hardie A et al. A prospective study of community-associated Clostridium difficile infections: the role of antibiotics and co-infections. J Infect 2014; 69: 134-144.
23. Naggie S, Frederick J, Pien BC et al. Community-associated Clostridium difficile infection: experience of a Veteran Affairs Medical Center in southeastern USA. Infection 2010; 38: 297-300.
24. McDonald LC, Coignard B, Dubberke E et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28: 140-145.
25. Centers for Disease Control and Prevention Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. Morb Mortal Wkly Rep 2005; 54: 1201-1205.
26. Otten AM, Reid-Smith RJ, Fazil A, Weese JS. Disease transmission model for community-associated Clostridium difficile infection. Epidemiol Infect 2010; 138: 907-914.
27. Kim KH, Fekety R, Batts DH et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981; 143: 42-50.
28. Rodriguez-Palacios A, Staempfli HR, Duffield T et al. Clostridium difficile in retail ground meat, Canada. Emerg Infect Dis 2007; 13: 485-487.
29. Hoover DG, Rodriguez-Palacios A. Transmission of Clostridium difficile in foods. Infect Dis Clin North Am 2013; 27: 675-685.
30. Songer JG, Trinh HT, Killgore GE et al. Clostridium difficile in retail meat products, USA, 2007. Emerg Infect Dis 2009; 15: 819-821.
31. Sambol SP, Merrigan MM, Lyerly D et al. Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun 2000; 68: 5480-5487.
32. Lessa FC Community-associated Clostridium difficile infection: how real is it? Anaerobe 2013; 24: 121-123.
33. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-2449.
34. Kachrimanidou M, Malisiovas N. Clostridium difficile infection: a comprehensive review. Crit Rev Microbiol 2011; 37: 178-187.
35. Dial S, Delaney JA, Barkun AN et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-2995.
36. Khanna S, Aronson SL, Kammer PP et al. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc 2012; 87: 636-642.
37. Donskey CJ, Sunkesula VC, Jencson AL et al. Utility of a commercial PCR assay and a clinical prediction rule for detection of toxigenic Clostridium difficile in asymptomatic carriers. J Clin Microbiol 2014; 52: 315-318.
38. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015; 313: 398-408.
39. Wilcox MH Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. Clin Microbiol Infect 2012; 18 Suppl 6: 13-20.
40. Su WY, Mercer J, Van Hal SJ et al. Clostridium difficile testing: have we got it right? J Clin Microbiol 2013; 51: 377-378.
41. McFarland LV, Surawicz CM, Rubin M et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20: 43-50.
42. Surawicz CM, McFarland LV, Greenberg RN et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31: 1012-1017.
43. O'Horo J, Safdar N. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. Int J Infect Dis 2009; 13: 663-667.
44. Lowy I, Molrine DC, Leav BA et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205.
45. Karczewski J, Zorman J, Wang S et al. Development ofa recombinant toxin fragment vaccine for Clostridium difficile infection. Vaccine 2014; 32: 2812-2818.
46. Foglia G, Shah S, Luxemburger C et al. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012; 30: 4307-4309.
47. Vindigni SM, Broussard EK, Surawicz CM. Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol 2013; 7: 615-628.
48. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
49. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002.
50. Kassam Z, Hundal R, Marshall JK et al. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med 2012; 172: 191-193.
51. Cammarota G, Masucci L, Ianiro G et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41: 835-843.
52. Konijeti GG, Sauk J, Shrime MG et al. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014; 58: 1507-1514.
53. Surawicz CM Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 2003; 17: 775-783.
54. Johnston BC, Ma SS, Goldenberg JZ et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 878-888.
55. Allen SJ, Wareham K, Wang D et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013; 382: 1249-1257.
56. Hacek DM, Ogle AM, Fisher A et al. Significant impact of terminal room cleaning with bleach on reducing nosocomial Clostridium difficile. Am J Infect Control 2010; 38: 350-353.